PT  - JOURNAL ARTICLE
AU  - Sara Maria da Costa Martins
AU  - Eduarda Tinoco
AU  - Bruno Cabrita
AU  - Daniela Machado
AU  - Inês Franco
AU  - Inês Ladeira
AU  - Ivone Pascoal
AU  - Ricardo Lima
AU  - Salete Valente
TI  - Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
AID  - 10.1183/13993003.congress-2021.PA3727
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3727
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3727.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3727.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: Nasal polyposis may impact asthma severity and is a frequent comorbidity in patients with severe eosinophilic asthma. Research has suggested mepolizumab may directly affect upper airway type 2 inflammatory conditions, however there is a lack of clinical studies confirming its effectiveness on nasal symptoms control.Aims: To assess the impact of mepolizumab on nasal symptoms control in patients with severe eosinophilic asthma and nasal polyposis.Methods: A multicenter retrospective study was performed in a cohort of patients with both nasal polyposis and severe refractory asthma treated with mepolizumab. Asthma-related parameters and sino-nasal clinical outcomes were analysed in baseline and 6-12 months after treatment initiation.Results: Twelve patients were included with an average age of 59 years at the start of mepolizumab therapy. The participants were predominantly females (75%) and 58% had history of sinus surgery. After at least 6 months of treatment with mepolizumab, effective control of asthma-related clinical parameters was observed, with a reduction in moderate to severe exacerbations and systemic corticosteroid therapy. In parallel, there was also a statistically significant improvement of sino-nasal symptoms and quality of life, evidenced by a reduction in the average total score on the Sino-Nasal Outcome Test 22, from 70 to 28 points (p= 0.008), and Nasal Congestion scale (range of severe symptoms (3) to mild (1), (p= 0.010)).Conclusions: Mepolizumab demonstrated clinical efficacy in controlling symptoms associated with nasal polyposis in patients with concomitant severe eosinophilic asthma, giving it the advantage of treating both conditions with the same intervention.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3727.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).